Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Making It Personal: Neoantigen Vaccines in Metastatic Melanoma.

Immunity - 15 Aug 2017

Hellmann Matthew D, Snyder Alexandra

Abstract excerpt

Somatic mutations in cancer can be translated into peptides, termed neoantigens, which can be recognized by the immune system as "foreign" epitopes. Two recent studies in Nature (Sahin et al., 2017; Ott et al., 2017) examine the effects of neoantigen vaccines on patients with stage III or IV melanoma and demonstrate immunogenicity and intriguing clinical safety and efficacy data in phase I studies.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Autoantigens
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase I as Topic

Share to Immunotherapy

Share to Neoplasm Metastasis

Share to Skin Neoplasms

Share to Vaccines, Subunit

Source

Identifiers

PMID: 28813655
DOI: 10.1016/j.immuni.2017.08.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Making It Personal: Neoantigen Vaccines in Metastatic Melanoma.PMID 28813655Read ↗

Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy.Semantic proximity Read ↗

An immunogenic personal neoantigen vaccine for patients with melanoma.Semantic proximity Read ↗

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.Semantic proximity Read ↗

Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.Semantic proximity Read ↗

Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patientsSemantic proximity Read ↗

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.Semantic proximity Read ↗

Personalized Cancer Vaccines Directed against Tumor Mutations: Building Evidence from Mice to Humans.Semantic proximity Read ↗

Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanomaSemantic proximity Read ↗

Individualised neoantigen cancer vaccine therapy.Semantic proximity Read ↗

Synthetic multiepitope neoantigen DNA vaccine for personalized cancer immunotherapy.Semantic proximity Read ↗

Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in MelanomaSemantic proximity Read ↗

Neoantigen Cancer Vaccines: Real Opportunity or Another Illusion?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.